Royal M, Roscigno R, et al. Preclinical and Phase 1 Clinical Characterization of LIQ861, a New Dry Powder Formulation of Treprostinil [poster]. In: World Symposium on Pulmonary Hypertension; 2018 February 27-March 1; Nice, France.

Royal M, Roscigno R, et al. Preclinical and Phase 1 Clinical Characterization of LIQ861, a New Dry Powder Formulation of Treprostinil [poster].  In: Pulmonary Vascular Research Institute (PVRI) Annual World Congress; 2018 January 21-24; Singapore, Asia.

Billiard J, et al.  Dry Powder Inhaled Ribavirin in Healthy Volunteers: Safety, Tolerability, Lung and Systemic Pharmacokinetics [poster].  In: European Respiratory Society International Congress; 2017 September 9-13; Milan, Italy.

PRINT nanoparticle-based delivery of immunostimulants and the MAGE-A3 antigen induces high IgG, CD4 +, & CD8+ T cell responses in swine” ; Michele Stone, Katie Horvath, Ashley Galloway, Christina Hofmann, Lara Kelly, Akihisa Nonoyama, Sean Meng, Andy Murphy, Loïc Le Gourrierec1, Pol Harvengt1, Christelle Langlet, Stéphane Temmerman1, Joelle Renneson, Nathalie Vanderheyde, Abdelatif Elouahabi, Sandra Morel. ImVacs abstract and poster presentation, Advances in Vaccine Technologies & Vaccine Adjuvant sessions, December 2016.  1 Liquidia Technologies;  2 GSK Vaccines, Belgium

PRINT Particles Enable Liquid Storage of Incompatible Components:  A case study with HibTT and DTaP” ; Ashley Galloway, Laurent Strodiot, Nadia Ouaked, Jin Lee, Patrick Pohlhaus, Ramya Yadavalli, Gabe Fawcett, Meredith Earl, Joseph Marchand, Marie-Noëlle Donner, Stéphane Temmerman, Nathalie Garçon, Eric De Buyl, Fabrice Godfroid, Abdelatif Elouahabi, and Michele Stone. ImVacs abstract and poster presentation, Advances in Vaccine Technologies & Vaccine Adjuvant sessions, December 2016.  1 Liquidia Technologies;  2 GSK Vaccines, Belgium

Precisely Molded Nanoparticle Displaying DENV-E Proteins Induces Robust Serotype-Specific Neutralizing Antibody Responses“; Stefan W. Metz , Shaomin Tian , Gabriel Hoekstra, Xianwen Yi, Michelle Stone, Katie Horvath, Michael J. Miley, Joseph DeSimone, Chris J. Luft , Aravinda M. de Silva; October 20, 2016; DOI: 10.1371/journal.pntd.0005071

Morton, S. W., Herlihy, K. P., Shopsowitz, K. E., Deng, Z. J., Chu, K. S., Bowerman, C. J., DeSimone, J. M. and Hammond, P. T. (2013), Scalable Manufacture of Built-to-Order Nanomedicine: Spray-Assisted Layer-by-Layer Functionalization of PRINT® Nanoparticles. Adv. Mater.. doi: 10.1002/adma.201302025

Maynor, B.; Garcia, A.; Tully, J.; Yerxa, B. “Application of PRINT® Microparticle and Nanoparticle Technology – Toward Preparation of Ophthalmic Suspension Formulations with Improved Tolerability and Efficacy”. ARVO abstract and poster presentation, Drug Delivery I session, May 2013.

Garcia, A.; Tully, J.; Maynor, B.; Yerxa, B. “Precisely Engineered Biodegradable Intraocular Implants for the Sustained Release of Dexamethasone”. ARVO abstract and poster presentation, Drug Delivery I session, May 2013.

“Development of a Nanoparticle-Based Iinfluenza Vaccine using the PRINT® Technology”; Galloway, A. L.; Murphy, A.; DeSimone, J. M.; Di, J.; Herrmann, J. P.; Hunter, M. E.; Kindig, J. P.; Malinoski, F. J.; Rumley, M. A.; Stoltz, D. M.; Templeman, T. S.; & Hubby, B. Nanomedicine: Nanotechnology, Biology and Medicine, May 2013, 9(4), pp. 523–531.

Particle Engineering for Inhalation Formulation and Delivery of Biotherapeutics”; Mack, P.; Horvath, K.; Garcia, A.; Tully, J.; and Maynor, B. Inhalation. August 2012.

“PEGylated PRINT® Nanoparticles: The Impact of PEG Density on Protein Binding, Macrophage Association, Biodistribution, and Pharmacokinetics”; Perry, J. L.#; Reuter, K. G.#; Kai, M. P.; Herlihy, K. P.; Jones, S. W.; Luft, J. C.; Napier, M. E.; Bear, J. E.; DeSimone, J. M.; Nanoletters, 2012, 12, 5304.

“Rendering Protein-based Particles Transiently Insoluble for Therapeutic Applications”; Xu, J.; Wang, J.; Luft, J. C.; Tian, S.; Owens, G.; Pandya, A.; Berglund, P.; Pohlhaus, P. D.; Maynor, B. W.; Napier, M. E.; DeSimone, J. M. J. Am. Chem. Soc. 2012, DOI: 10.1021/ja302363r.

“Reductively-Responsive siRNA-Conjugated Hydrogel Nanoparticles for Gene Silencing”; Dunn, S. S.; Tian, S.; Blake, S.; Wang, J.; Galloway, A. L.; Murphy, A.; Pohlhaus, P. D.; Rolland, J. P.; Napier, M. E.; and DeSimone, J. M. J. Am. Chem. Soc., Just Accepted Manuscript • DOI: 10.1021/ja300174v • Publication Date (Web): 05 Apr 2012.

“Delivery of Multiple siRNAs Using Lipid-coated PLGA Nanoparticles for treatment of Prostate Cancer”; Hasan, W.; Chu, K.; Gullapalli, A.; Dunn, S. S.; Enlow, E.; Luft, J. C.; Tian, S.; Napier, M.E.; Pohlhaus, P. D.; Rolland, J. P.; DeSimone*, J. M. NanoLetters 2012, 12, 287-292.

Microfabricated Engineered Particle Systems for Respiratory Drug_Delivery and Other Pharmaceutical Applications” ;Garcia, A.; Mack, P.; Williams, S.; Fromen, C.; Shen, T.; Tully, J.; Pillai, J.; Kuehl, P.; Napier, M. E.; DeSimone, J. M.; and Maynor, B. Journal of Drug Delivery. 2012

“Engineering Nanomedicines Using Stimuli-responsive Biomaterials”; Wang, Y.; Byrne, J. D.; Napier, M. E.; DeSimone*, J. M. Advanced Drug Delivery Reviews 2011, in press.

Microfabricated, Engineered Particles for Efficient Inhalation Drug Delivery”; Maynor, B. W.; Presented at Drug Delivery to the Lungs 22, December 2011.

“PRINT®: A Novel Platform Toward Shape and Size Specific Nanoparticle Theranostics”; Perry, J. L.; Herlihy, K. P.; Napier, M. E.; DeSimone*, J. M. Accounts of Chemical Research 2011, 44(10), 990-998.

“Engineering More Effective Nanomedicines Through Particle Design”; Wang, J.; Byrne, J. D.; Napier, M. E.; DeSimone*, J. M. Small 2011, 7(14), 1919-1931.

Ashley L. Galloway, Andrew Murphy, Jason P. Rolland, Kevin P. Herlihy, Robby A. Petros, Mary E. Napier, and Joseph M. DeSimone; “Micromolding for the Fabrication of Biological Microarrays” in Biological Microarrays: Methods and Protocols; Eds A. Khademhosseini; K.-Y Suh; M. Zourob; 2011; pp. 249-260.

“Novel Platforms for Vascular Carriers with Controlled Geometry”; Pillai, J.; Dunn, S. S.; Napier, M. E.; DeSimone*, J. M. International Union of Biochemistry and Molecular Biology: Life 2011, 63(8), 596-606.

Control of Nano- and Micro-Particle Size, Shape, Dispersity and Elasticity: Development of Vaccine and Therapeutic Particles for Use in Parenteral and Inhalation Routes of Administration. Presented at SMART Drug Delivery Workshop , Washington, DC.DeSimone, J.M.; Mack, P.D. (2011, August).

PRINT® Particles and Well Arrays for Next Generation Sequencing; Knutson, T.; Maynor, B.; Nijhawan, A. 2011

Using mechanobiological mimicry of red blood cells to extend circulation times of hydrogel microparticles“; Merkel, T. J.; Jones, S. W.; Herlihy, K. P.; Kersey, F. R.; Shields, A. R.; Napier, M.; Luft, J. C.; Wu, H.; Zamboni, W. C.; Wang, A. Z.; Bear, J. E.; and DeSimone, J. M., Proceedings of National Academy of Sciences 2011, 108(2) 586-591.

“Potent Engineered PLGA Nanoparticles by Virtue of Exceptionally High Chemotherapeutic Loadings“; Enlow, E.M.; Luft, J.C.; Napier, M.E.; DeSimone, J.M., Nano Letters 2011, (DOI: 10.1021/nl104117p).

“Tunable Bi-functional Silyl Ether Cross-Linkers for the Design of Acid Sensitive Biomaterials”; Parrott, M. C.; Luft, J. C.; Byrne, J. D.; Fain, J. H.; Napier, M. E.; DeSimone*, J. M. J. Am. Chem. Soc. 2010, 132(50), 17928-17932.

“Microfabricated, Shape-Specific Particles and Engineered Aerosols for Efficient Aerosol Delivery to the Lung”;Maynor B.W.; Garcia, A.; Duong, H.; Mack, P. Respiratory Drug Delivery 2010 , 2010 Vol 2, pp 619-622

PRINT® Technology: Enabling Next Generation Sequencing“; Knutson, T.; Maynor, B.; Zhou, Z.; Chenet, K. 2010.

The Complex Role of Multivalency in Nanoparticles Targeting the Transferrin Receptor for Cancer Therapies“; Wang, J.; Tian, S.; Petros, R. A.; Napier, M. E.; DeSimone*, J. M. J. Am. Chem. Soc. 2010, 132 (32), pp 11306–11313 (DOI: 10.1021/ja1043177)

Nanomanufacturing: The Missing Link between Discovery and Products [White Paper]. Rothrock, G., Pishny,E., & DeSimone, J. 2009.

Top-down Particle Fabrication: Control of Size and Shape for Diagnostic Imaging and Drug Delivery“; Canelas, D. A.; Herlihy, K. P.; DeSimone*, J. M. Advanced Reviews Wiley 2009, 1 (4), 391-404.

The Effect of Particle Design on Cellular Internalization Pathways“; Gratton, S. E. A.; Ropp, P. A.; Pohlhaus, P. D.; Luft, J. C.; Madden, V. J.; Napier, M. E.; DeSimone*, J. M. Proceedings of the National Academy of Sciences2008, 105(33), 11613-11618.

Shape-specific, Mono-disperse Nano-molding of Protein Particles“; Kelly, J. Y.; DeSimone*, J. M. J. Am. Chem. Soc. 2008, 130, 5438-5439.

Microfabricated Particles for Engineered Drug Therapies: Elucidation into the Mechanisms of Cellular Internalization of PRINT® Particles“; Gratton, S. E. A.; Napier, M. E.; Ropp, P. A.; Tian, S. DeSimone*, J. M.Pharm. Res. 2008, 25, 2845-2852.

Reductively Labile PRINT® Nanoparticles for the Delivery of Doxorubicin to HeLa Cells“; Petros, R. A.; Ropp, P. A.; DeSimone*, J. M.; J. Am. Chem. Soc. 2008, 130, 5008-5009.

The Pursuit of a Scalable Nano-fabrication Platform for Use in Material and Life Science Applications“; Gratton, S. E. A.; Williams, S. S.; Napier, M. E.; Pohlhaus, P. D.; Zhou, Z.; Wiles, K. B.; Maynor, B. B.; Shen, C.; Olafsen, T.; Samulski, E. T.; DeSimone*, J. M. Accounts of Chemical Research 2008, 41, 1685-1695.

“Nanoparticle Drug Delivery Platform“; Napier, M. E.; DeSimone*; J. M. Polymer Reviews 2007, 47, 321-327

Nanofabricated Particles for Engineered Drug Therapies: A Preliminary Biodistribution Study of PRINT® Nanoparticles“; Gratton, S. E. A.; Pohlhaus, P. D.; Lee, J.; Guo, J.; Cho, M. J.; DeSimone*, J. M. J. Controlled Release 2007, 121, 10-18.

Imparting Size, Shape, and Composition Control of Materials for Nanomedicine“; Eulis, L.; DuPont, J.; DeSimone*, J. M. Chem. Soc. Rev. 2006, 35, 1095-1104.

Direct Fabrication and Harvesting of Monodisperse, Shape Specific Nano-Biomaterials“; Rolland, J. P.; Maynor, B. W.; Euliss, L. E.; Exner, A. E.; Denison, G. M.; DeSimone*, J. M J. Am. Chem. Soc. 2005, 127, 10096-10100.

© 2018 Liquidia Technologies